Overview
Paris – April 25, 2025 – McDermott Will & Emery is advising LifeSci Capital LLC, Van Lanschot Kempen N.V. and Van Lanschot Kempen (USA) Inc, acting as placement agents, in connection with the financing of DBV Technologies for an amount of up to $306.9 million (€284.5 million) through a private placement of shares (PIPE), with the issuance of 34,090. 004 new shares to which share subscription warrants (ABSA) are attached, and 71,005,656 pre-financed share subscription warrants to which warrants allowing subscription to pre-financed share subscription warrants (PFW-BS-PFW) are attached.
This financing will enable DBV, a clinical-stage biopharmaceutical company specializing in the development of treatment options for food allergies and other immunological conditions with significant unmet medical needs, listed on Euronext Paris and the Nasdaq Capital Market, to advance the development of its Viaskin® Peanut program through to the filing of a Biologics License Application (BLA), and to ensure commercialization of the product in the United States, if the BLA is approved.
The McDermott team involved in this transaction comprised:
– Bertrand Delafaye, David Revcolevschi, Partners, Lucie Martin, Counsel, and Agathe Bourdillon, Associate.
About McDermott
Leading organizations turn to global law firm McDermott Will & Emery for a better way to address legal challenges, connect with those at the forefront, and drive stronger outcomes. Working across more than 20 offices globally, our 1,400+ lawyers act on data-driven insights, deep relationships, and unmatched industry experience to deliver on our commitment of Always Better.
